Intelligent Investor

Metal Tiger Plc (ASX: MTR) - Announcements

- Current share price for MTR : $0.325

ASX company news and announcements for Metal Tiger Plc (MTR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Metal Tiger Plc (MTR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Metal Tiger Plc (MTR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Metal Tiger Plc (MTR)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
- Share Purchase Plan 27 Mar 2015 3:33PM $3.390 $0.325 $0.325 fallen by 90.41%
- Completion of Placement 20 Mar 2015 8:55AM $3.240 $0.325 $0.325 fallen by 89.97%
- Trading Halt 19 Mar 2015 8:53AM $3.240 $0.325 $0.325 fallen by 89.97%
- Appendix 4D and Half Year Financial Statements 27 Feb 2015 8:53AM n/a $0.325 $0.325 n/a
- Appendix 4E and FY2014 Financial Report 29 Aug 2014 9:05AM $2.370 $0.325 $0.325 fallen by 86.29%
- ASX Market Release - Admission 20 Jun 2014 8:49AM $1.780 $0.325 $0.325 fallen by 81.74%
- Suspension from Official Quotation cob 09/08/06 2 Aug 2006 11:30AM $0.105 $0.325 $0.325 risen by 209.52%
- ACL ann: Alchemia Offer - Extension of Offer Period 7 Jul 2006 2:56PM n/a $0.325 $0.325 n/a
- Patient Accrual Closes for HyCAMP Phase II Study 14 Jun 2006 9:48AM $0.115 $0.325 $0.325 risen by 182.61%
- ACL: ACL Extends MTR Offer for 2 Weeks 9 Jun 2006 4:33PM $0.115 $0.325 $0.325 risen by 182.61%
- Supplementary Bidder's Statement 31 May 2006 4:25PM $0.135 $0.325 $0.325 risen by 140.74%
- ACL: Alchemia declares offer unconditional 29 May 2006 9:22AM $0.135 $0.325 $0.325 risen by 140.74%
- First Supplementary Target's Statement 26 Apr 2006 3:46PM $0.130 $0.325 $0.325 risen by 150%
- Target's Statement - Off-market bid 30 Mar 2006 4:59PM $0.135 $0.325 $0.325 risen by 140.74%
- Preliminary Final Report 10 Mar 2006 2:51PM $0.130 $0.325 $0.325 risen by 150%
- Alchemia and Meditech to merge 9 Mar 2006 9:42AM $0.120 $0.325 $0.325 risen by 170.83%
- Response to ASX Share Price Query 11 Oct 2005 3:31PM $0.140 $0.325 $0.325 risen by 132.14%
- Half Yearly Report & Half Year Accounts 31 Aug 2005 9:37AM $0.098 $0.325 $0.325 risen by 231.63%
- Offered $2.98m AusIndustry Commercialisation Grant 24 Aug 2005 9:30AM $0.120 $0.325 $0.325 risen by 170.83%
- Signs Collaboration Agreement with Hyalose 7 Jul 2005 9:20AM $0.097 $0.325 $0.325 risen by 235.05%
- Cancer Drug Phase II Trial:1st Patient Enrolled & Treated 3 Dec 2004 9:34AM $0.210 $0.325 $0.325 risen by 54.76%
- MTR & Griffith University ann Research Collaboration 12 Nov 2004 12:45PM $0.225 $0.325 $0.325 risen by 44.44%
- HyCamp Clinical Trial - Early Positive Results 20 Apr 2004 10:29AM $0.290 $0.325 $0.325 risen by 12.07%
- Half Yearly Report 27 Feb 2004 10:05AM $0.270 $0.325 $0.325 risen by 20.37%
- MTR&Novozymes enter into collaboration&licensing agmt 19 Dec 2003 9:14AM $0.310 $0.325 $0.325 risen by 4.84%

501 - 525 of 530 results

Page 21 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.